Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration

Lykke M Ørnbjerg¹, Louise Linde², Stylianos Georgiadis¹, Simon H Rasmussen³, Ulf Lindström⁴, Johan Askling⁵, Brigitte Michelsen⁶, Daniela Di Giuseppe⁷, Johan K Wallman⁸, Karel Pavelka⁹, Jakub Závada⁹, Michael J Nissen¹⁰, Gareth T Jones¹¹, Heikki Relas¹², Laura Pirilä¹³, Matija Tomšič¹⁴, Ziga Rotar¹⁴, Arni Jon Geirsson¹⁵, Bjorn Gudbjornsson¹⁶, Eirik K Kristianslund¹⁷, Irene van Sder Horst-Bruinsma¹⁸, Anne Gitte Loft¹⁹, Karin Laas²⁰, Florenzo Iannone²¹, Addolorata Corrado²², Adrian Ciurea²³, Maria J Santos²⁴, Helena Santos²⁵, Catalin Codreanu²⁶, Nurullah Akkoc²⁷, Ozgul S Gunduz²⁷, Bente Glintborg²⁸, Mikkel Østergaard²⁹, Merete Lund Hetland²⁹

Affiliations

¹ Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark; DANBIO registry, Rigshospitalet, Glostrup, Denmark.
² Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark; DANBIO registry, Rigshospitalet, Glostrup, Denmark. Electronic address: louise.linde@regionh.dk.
³ Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark.
⁴ Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
⁵ Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
⁶ Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark; Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway; Division of Rheumatology, Department of Medicine, Hospital of Southern Norway Trust, Kristiansand, Norway.
⁷ Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
⁸ Department of Clinical Sciences Lund, Rheumatology, Skåne University Hospital, Lund University, Lund, Sweden.
⁹ Institute of Rheumatology, Prague, Czech Republic; Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
¹⁰ Department of Rheumatology, Geneva University Hospital, Geneva, Switzerland.
¹¹ Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, Aberdeen, UK.
¹² Department of Rheumatology, Inflammation Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
¹³ Center for Rheumatology and Clinical Immunology, Division of Medicine, Turku University Hospital, Turku, Finland; Department of Internal Medicine, Department of Clinical Medicine, University of Turku, Turku, Finland.
¹⁴ Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia; Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
¹⁵ Department of Rheumatology, University Hospital, Reykjavik Iceland.
¹⁶ Centre for Rheumatology Research, Landspitali, University Hospital, Reykjavik, Iceland; Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
¹⁷ Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.
¹⁸ Department of Rheumatology, Radboud UMC, Nijmegen, the Netherlands.
¹⁹ Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
²⁰ Department of Rheumatology, East-Tallinn Central Hospital, Tallinn, Estonia.
²¹ Rheumatology Unit, DETO, University of Bari, Bari, Italy.
²² Rheumatology Unit, Department of Medical and Surgical Sciences, University of Foggia, Italy.
²³ Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
²⁴ Serviço de Reumatologia, Hospital Garcia de Orta, Almada, Portugal; Reuma.pt, Sociedade Portuguesa de Reumatologia, Lisbon, Portugal.
²⁵ Reuma.pt, Sociedade Portuguesa de Reumatologia, Lisbon, Portugal; Instituto Português de Reumatologia, Lisbon, Portugal; EpiDoc Unit, Nova Medical School, Lisbon, Portugal.
²⁶ Center for Rheumatic Diseases, University of Medicine and Pharmacy, Romanian Registry of Rheumatic Diseases, Bucharest, Romania.
²⁷ Division of Rheumatology, Department of Medicine, Celal Bayar University Hospital, Manisa Turkey.
²⁸ Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark; DANBIO registry, Rigshospitalet, Glostrup, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
²⁹ Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

PMID: 35985172
DOI: 10.1016/j.semarthrit.2022.152081

Free article

Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration

Lykke M Ørnbjerg et al. Semin Arthritis Rheum. 2022 Oct.

Free article

. 2022 Oct:56:152081.

doi: 10.1016/j.semarthrit.2022.152081. Epub 2022 Aug 10.

Authors

Affiliations

¹ Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark; DANBIO registry, Rigshospitalet, Glostrup, Denmark.
² Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark; DANBIO registry, Rigshospitalet, Glostrup, Denmark. Electronic address: louise.linde@regionh.dk.
³ Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark.
⁴ Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
⁵ Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
⁶ Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark; Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway; Division of Rheumatology, Department of Medicine, Hospital of Southern Norway Trust, Kristiansand, Norway.
⁷ Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
⁸ Department of Clinical Sciences Lund, Rheumatology, Skåne University Hospital, Lund University, Lund, Sweden.
⁹ Institute of Rheumatology, Prague, Czech Republic; Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
¹⁰ Department of Rheumatology, Geneva University Hospital, Geneva, Switzerland.
¹¹ Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, Aberdeen, UK.
¹² Department of Rheumatology, Inflammation Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
¹³ Center for Rheumatology and Clinical Immunology, Division of Medicine, Turku University Hospital, Turku, Finland; Department of Internal Medicine, Department of Clinical Medicine, University of Turku, Turku, Finland.
¹⁴ Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia; Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
¹⁵ Department of Rheumatology, University Hospital, Reykjavik Iceland.
¹⁶ Centre for Rheumatology Research, Landspitali, University Hospital, Reykjavik, Iceland; Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
¹⁷ Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.
¹⁸ Department of Rheumatology, Radboud UMC, Nijmegen, the Netherlands.
¹⁹ Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
²⁰ Department of Rheumatology, East-Tallinn Central Hospital, Tallinn, Estonia.
²¹ Rheumatology Unit, DETO, University of Bari, Bari, Italy.
²² Rheumatology Unit, Department of Medical and Surgical Sciences, University of Foggia, Italy.
²³ Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
²⁴ Serviço de Reumatologia, Hospital Garcia de Orta, Almada, Portugal; Reuma.pt, Sociedade Portuguesa de Reumatologia, Lisbon, Portugal.
²⁵ Reuma.pt, Sociedade Portuguesa de Reumatologia, Lisbon, Portugal; Instituto Português de Reumatologia, Lisbon, Portugal; EpiDoc Unit, Nova Medical School, Lisbon, Portugal.
²⁶ Center for Rheumatic Diseases, University of Medicine and Pharmacy, Romanian Registry of Rheumatic Diseases, Bucharest, Romania.
²⁷ Division of Rheumatology, Department of Medicine, Celal Bayar University Hospital, Manisa Turkey.
²⁸ Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark; DANBIO registry, Rigshospitalet, Glostrup, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
²⁹ Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

PMID: 35985172
DOI: 10.1016/j.semarthrit.2022.152081

Erratum in

Corrigendum to 'Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: data from the EuroSpA collaboration' [Seminars in Arthritis and Rheumatism 56 (2022) 1-13/152081].
Ørnbjerg LM, Linde L, Georgiadis S, Rasmussen SH, Lindström U, Askling J, Michelsen B, Giuseppe DD, Wallman JK, Pavelka K, Závada J, Nissen MJ, Jones GT, Relas H, Pirilä L, Tomšič M, Rotar Z, Geirsson AJ, Gudbjornsson B, Kristianslund EK, van der Horst-Bruinsma I, Loft AG, Laas K, Iannone F, Corrado A, Ciurea A, Santos MJ, Santos H, Codreanu C, Akkoc N, Gunduz OS, Glintborg B, Østergaard M, Hetland ML. Ørnbjerg LM, et al. Semin Arthritis Rheum. 2023 Feb;58:152141. doi: 10.1016/j.semarthrit.2022.152141. Epub 2022 Dec 1. Semin Arthritis Rheum. 2023. PMID: 36463635 No abstract available.

Abstract

Objectives: In patients with axial spondyloarthritis (axSpA) initiating their first tumor necrosis factor alpha-inhibitor (TNFi), we aimed to identify common baseline predictors of Ankylosing Spondylitis Disease Activity Score (ASDAS-CRP) inactive disease (primary objective) and clinically important improvement (CII) at 6 months, and drug retention at 12-months across 15 European registries.

Methods: Baseline demographic and clinical characteristics were collected. Outcomes were investigated per registry and in pooled data using logistic regression analyses on multiply imputed data.

Results: The consistency of baseline predictors in individual registries justified pooling the data. In the pooled dataset (n = 21,196), the 6-month rates for ASDAS inactive disease and ASDAS CII were 26% and 51%, and the 12-month drug retention rate 65% in patients with available data (n = 9,845, n = 6,948 and n = 21,196, respectively). Nine common baseline predictors of ASDAS inactive disease, ASDAS CII and 12-month drug retention were identified, and the odds ratios (95%-confidence interval) for ASDAS inactive disease were: age, per year: 0.97 (0.97-0.98), men vs. women: 1.88 (1.60-2.22), current vs. non-smoking: 0.76 (0.63-0.91), HLA-B27 positive vs. negative: 1.51 (1.20-1.91), TNF start year 2015-2018 vs. 2009-2014: 1.24 (1.06-1.45), CRP>10 vs. ≤10 mg/l: 1.49 (1.25-1.77), one unit increase in health assessment questionnaire (HAQ): 0.77 (0.58-1.03), one-millimeter (mm) increase in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) fatigue and spinal pain: 0.99 (0.99-1.00) and 0.99 (0.99-1.99), respectively CONCLUSION: Common baseline predictors of treatment response and adherence to TNFi could be identified across data from 15 European registries, indicating that they may be universal across different axSpA populations.

Keywords: Ankylosing spondylitis disease activity score; Axial spondyloarthritis; Predictors; TNF-inhibitors.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest LMØ, LL, SG and SHR: research grants from Novartis; UL: none; DDG none; JKW: consultant of AbbVie, Amgen, Celgene, Eli Lilly and Novartis; BG: research grants from Pfizer, Abbvie and BMS; LP: consultant of Novartis Finland, UCB Pharma, Pfizer, Sanofi, BMS, AbbVie, Amgen, Celgene, Eli Lilly, Boehringer-Ingelheim, Mylan; KL: consulting and/or speaking fees from Amgen, Johnson and Johnson and Novartis; ACo: research grants, consulting and/or speaking fees from Amgen, Lilly, Pfizer, Boehringer Ingelheim; KP: speaker and consulting fees from Pfizer, MSD, BMS, UCB, Amgen, Egis, Roche, AbbVie; JZ: speaker and consulting fees from Abbvie, Elli-Lilly, Sandoz, Novartis, Egis, UCB; EKK: none; NA: speaking fees from Pfizer; ÖSG: none; HS: research grant from Sociedade Portuguesa de Reumatologia and speaker and/or consultancy fees from Abbvie, Janssen, Lilly, Novartis and Pfizer; MJN: consulting and/or speaking fees from AbbVie, Eli Lilly, Janssens, Novartis and Pfizer; BM: research grant from Novartis; GTJ: research grants from AbbVie, Pfizer, UCB, Amgen, GSK. Speaker fee from Janssen; HR: consulting and/or speaking fees from Abbvie, Celgene, Pfizer, UCB, and Viatris; MT: consulting and/or speaking fees from Abbvie, Amgen, Biogen, Eli Lilly, Janssen, Medis, MSD, Novartis, Pfizer, Sanofi, Sandoz-Lek; AJG: none; IHB: Consultant for Abbvie, UCB, MSD, Novartis, Lilly, unrestricted Grants received for investigator initiated studies from: MSD, Pfizer, AbbVie, UCB, fees received for Lectures from BMS, AbbVie, Pfizer, MSD ; JA: PI for agreements between Karolinska Institutet and Abbvie, Astra-Zeneca, BMS, Eli Lilly, Janssen, MSD, Pfizer, Roche, Samsung Bioepis, Sanofi, and UCB; FI: consulting and/or speaking from Abbvie, Amgen, AstraZeneca, BMS, Galapagos, Janssen, Lilly, MSD, Novartis, Pfizer, Roche and UCB; AGL: Research Grant from Novartis, and speaker and/or consultancy fees from AbbVie, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, and UCB; ACi: consulting and/or speaking fees from AbbVie, Eli Lilly, Merck Sharp & Dohme, Novartis and Pfizer; MJS: speaker fees from Abbvie, AstraZeneca, Lilly, Novartis and Pfizer; CC: Speaker and consultancy fees from AbbVie, Amgen, Boehringer Ingelheim, Ewopharma, Lilly, Novartis, Pfizer; ZR: speaker or consultancy fees from Abbvie, Novartis, MSD, Medis, Biogen, Eli Lilly, Pfizer, Sanofi, Lek, Janssen; BjG: consulting and/or speaking fees from Amgen and Novartis; MØ: research grants from Abbvie, BMS, Merck, Celgene and Novartis, and speaker and/or consultancy fees from Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, Sandoz, Sanofi and UCB; MLH: Research grants from Abbvie, Biogen, BMS, Celltrion, Eli Lilly, Janssen Biologics B.V, Lundbeck Fonden, MSD, Medac, Pfizer, Roche, Samsung Biopies, Sandoz, Novartis.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration

Affiliations

Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration

Authors

Affiliations

Erratum in

Abstract

Conflict of interest statement

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Research Materials

Miscellaneous